Trinbelimab

Trinbelimab (r-anti-D) is a recombinant anti-Rh (o) -D immunoglobulin. Trinbelimab can be used for the prevention of immune reactions caused by Rh (D) blood group incompatibility between mother and fetus, as well as for research on hemolytic disease of the fetus/newborn (HDFN) [1].

Product Specifications

CAS Number

[2415078-44-1]

Product Name Alternative

R-anti-D

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Others

Assay Protocol

https://www.medchemexpress.com/trinbelimab.html

Purity

Solubility

10 mM in DMSO

Smiles

[Trinbelimab]

Molecular Weight

(145.47 kDa)

References & Citations

[1]Rahul Vishwanath Mayekar, et al. Recombinant anti-D for prevention of maternal-foetal Rh (D) alloimmunization: a randomized multi-centre clinical trial. Obstet Gynecol Sci. 2020 May;63 (3) :315-322.